1. Insights
  2. News
  3. Press Releases

Akin Gump Advises BioPharma Credit Investment Funds in $200 Million Loan Agreement for Lexicon Pharmaceuticals

December 5, 2017

Reading Time : 1 min
Jump to
View People Mentioned in This NewsView Related Services, Sectors, and Regions

Contact:

Jacinta O'Shea-Ramdeholl

Director of Communications

Send Email
+1 212.407.3080

Scott Wasserman

Senior Media Relations Manager

Send Email
+1 212.407.3009

(New York) – Lexicon Pharmaceuticals, Inc. has announced that it has entered into a definitive term loan agreement with BioPharma Credit PLC and BioPharma Credit Investments IV Sub LP, investment funds managed by Pharmakon Advisors, LP. The agreement provides Lexicon with up to $200 million of borrowing capacity available in two tranches, each maturing in December 2022 and bearing interest at 9.0 percent per annum. Akin Gump advised BioPharma Credit PLC and BioPharma Credit Investments IV Sub LP in the matter.

Akin Gump partner Geoffrey Secol led the team advising the two funds managed by Pharmakon. He was joined by senior counsel Miriam Foley, associate Amanda Lui and partner Ron Grabov-Nardini.

Founded in 1945, Akin Gump Strauss Hauer & Feld LLP is a leading international law firm with more than 900 lawyers in offices throughout the United States, Europe, Asia and the Middle East.

# # #

Share This Insight

Related Services, Sectors, and Regions

© 2024 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.